12. Discourage and refrain from funding national evaluation studies that would be duplicative of studies done for WHO PQ listing or SRA approval.
13. Fund impactful technologies and interventions quickly.
14. Support in a transparent manner the procurement of commodities and operational costs to maintain and further scale-up POC EID, as well as viral load testing for infants, children, and pregnant and breastfeeding women, as an integral part of optimized and integrated national laboratory networks and in accordance with national EID and VL plans and targets.
15. Support the development of a competitive, healthy, and sustainable market for POC and laboratory technologies.
16. Continue to support WHO PQ to shorten timelines for dossier review and minimize time to national registration.
45. Support countries’ TB case finding strategies that address children and country-level uptake and scaling up of new tools for TB diagnosis in children, as per international guidance.
46. Support more coordinated diagnostic network strengthening and optimization exercises, led by national governments, across diseases (TB and HIV as well as other key diagnostics).
On the efforts to mitigate the impact of COVID on TB detection and care through the C19 response mechanism in 2020: The Global Fund will continue its COVID-19 Response Mechanism, C19RM, in 2021.
54. Support GAP-f partners’ plan for the accelerated introduction and rollout of the DTG 10mg dispersible tablet formulation in priority countries to ensure early and wide uptake.
55. Support stakeholders involved in accelerated introduction and rollout of the 4-in-1 formulation as an alternative regimen for young children.
21. Support catalytic procurement of all or part of initial validation batches from manufacturers such that product availability is not delayed once approval or tentative approval is achieved.
22. Incentivize commercialization of new pediatric ARV products “at risk” to accelerate introduction and scale up of new paediatric ARV product such that product is available at time of approval/tentative approval/prequalification.
102. When negotiating grants, encourage countries to address health product management and domestic procurement challenges that may negatively affect the procurement of quality, affordable health products, including the procurement of small volume or small market products, such as pediatric DS and DRTB drugs.
103. Continue to use a flexible approach in the implementation of the co-financing policy, particularly related to small volume, small market products that might be more challenging to procure effectively via domestic procurement.
104. With partners, support and encourage countries to adequately prepare to procure small volume, small market products as they increase their role in domestic procurement and encourage the use of international pooled procurement platforms. In alignment with recommendations from the United Nations High Level Meeting on Tuberculosis in 2018, encourage the use of STBP/GDF when countries are unable to efficiently procure such products directly from suppliers.